Detect lung cancer with a nanotech breathalizer? It works, four out of five times, could revolutionize cancer screening

Researchers have been working for several years on a way to detect lung cancer in patients by analyzing their breath. It appears that they are close to having a working device. An international team of researchers presented their work, a breath test that can detect lung cancer, at the recent American Society of Clinical Oncology meeting in Chicago. The researchers reported that the device could accurately detect lung cancer in four out of five cases. A small version of the device can plug into a computer’s USB port.

The device, which can detect the unique smell of cancer cells, can ever differentiate between subtypes, and can tell how advanced the disease is. Study author Dr. Nir Peled, an oncologist with the Davidoff Cancer Center in Israel explained, “The more tumor you have, the more robust signature you produce.”

A lung cancer breathalyzer could substantially impact survival rates. Researchers have developed a device that works with up to 90 per cent accuracy in detecting lung cancer by analyzing volatile organic compounds in the patients’ breath.

The device could “totally revolutionize” lung cancer screening and diagnosis, Peled said. It can provide a “nontraumatic, easy, cheap approach to early detection and differentiation of lung cancer,” said study co-author Dr. Fred Hirsch, an investigator at the University of Colorado Cancer Center and professor at the University of Colorado School of Medicine in Denver.

Lung cancer is the top cancer killer in the United States. The tumors produce volatile organic compounds (VOCs), which the device’s NaNose nanotech chip can detect from a person’s breath. The ability to detect tumors earlier would be a big advantage and could “substantially impact survival.”

In the tests, conducted in the United States and in Israel, patients blew into a balloon that was attached to a gold nanoparticle sensor. Particles trapped in the sensor were analyzed for VOCs. Early-stage lung cancer patients were identified 85 per cent of the time; healthy people were distinguished from those with advanced-stage lung cancer 82 per cent of the time.

US company Alpha Szenszor has acquired the licence for the technology and is working to bring it to market “within the next few years.”

Did you miss this?

Other Popular Stories

  • Scientists claim 30 per cent improvement in solar cell efficiency
  • Utility offers customers Tesla Powerwalls as home energy storage market heats up
  • Robots, 3D printing to revolutionize building industry unchanged for 5000 years
  • Manufacturing sector rebounded in February: Statistics Canada
  • Ontario increases incentives for EV buyers
  • Local Ford union rebellion over GM contract threatens pattern bargaining
  • Canadian Solar could earn $2.3 billion through acquisition of Recurrent Energy
  • Little certainty about toxicity of BPA in food cans despite new report
  • Ontario must develop its cybersecurity industry to remain competitive: report
  • Tiangong-1 Update
  • Canada could lead the world in cleantech: report
  • Windsor auto industry growing, needs skilled workers: report
  • Highly Accurate Counting Technique from National Institute of Standards and Technology
  • China’s Drive for Clean Energy Results in Winter Gas Shortage
  • Canada could get 35 per cent of its power from wind with no disruption to existing grid: study
  • Manufacturing index rises, conditions "robust" in October: RBC
  • Safer tank cars coming as railways ship more oil than ever
  • Auto sales surging in North America, plunging in Russia
  • Province lends steel maker $7 million for plant upgrades
  • Number of reported pipeline spills in Canada doubled over ten years
Scroll to Top